azd-4547
Small moleculeexperimental
Clinical trial activity
15 trials · 27 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00979134)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Glioma · Phase 2
- Kidney Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2/Phase 3
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Mutation · Phase 2/Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacokinetics · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Receptors, Fibroblast Growth Factor · Phase 2/Phase 3
- Skin Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Fibroblast growth factor receptorINHIBITOR
Fibroblast growth factor receptor inhibitor
Compound can be found in AstraZeneca's clinical compound bank for OpenInnovation opportunities.
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1- Mol. weight
- 463.58 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3184679 ↗
Also known as
- azd4547
- azd4547
- azd 4547
- azd 4547
- azd-4547
- azd-4547
- azd-4547
- kb-74810
- kb-74810
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02546661 | Phase 1 | Oct 3, 2016 | AstraZeneca, SCRI Development Innovations, University of London |
| NCT02824133 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | University of Paris |
| NCT02465060 | Phase 2 | Aug 12, 2015 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT02664935 | Phase 2 | Mar 1, 2015 | AstraZeneca, Cancer Research UK, Pfizer, University of Birmingham |
| NCT02154490 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2014 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT02965378 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2014 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT02117167 | Phase 2 | Apr 23, 2014 | AstraZeneca, Fondation ARC, Groupe Hospitalier Paris Saint Joseph, Institut Gustave Roussy, UNICANCER |
| NCT02299999 | Phase 2 | Apr 7, 2014 | AstraZeneca, Fondation ARC, Institut Gustave Roussy, UNICANCER |
| NCT01824901 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2013 | Eastern Cooperative Oncology Group, ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
| NCT01795768 | Phase 2 | Sep 1, 2012 | AstraZeneca, Royal Marsden Hospital NHS Trust |
| NCT01791985 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | AstraZeneca, Burton Hospitals NHS Foundation Trust, Cancer Research UK, Newcastle University, Poole Hospital NHS Foundation Trust, The Christie NHS Foundation Trust, The Dudley Group NHS Foundation Trust, University of Cambridge, University of Glasgow, University of London |
| NCT01457846 | Phase 2 | Nov 1, 2011 | AstraZeneca, Katholieke Universiteit Leuven, Seoul National University |
| NCT01202591 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | AstraZeneca |
| NCT01213160 | Phase 1 | Nov 1, 2010 | AstraZeneca, Hokkaido University, National Hospital Organisation Nagoya Medical Centre |
| NCT00979134 | Phase 1 | Oct 1, 2009 | AstraZeneca |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 10 | 5 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 2 | 2013 |
| Cancer Research UK | Academic/Hospital | 2 | 0 | 1 | 2012 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 2 | 1 | 1 | 2013 |
| Fondation ARC | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Institut Gustave Roussy | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Southwest Oncology Group | Academic/Hospital | 2 | 2 | 1 | 2014 |
| UNICANCER | Academic/Hospital | 2 | 2 | 1 | 2014 |
| University of London | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Burton Hospitals NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Groupe Hospitalier Paris Saint Joseph | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Hokkaido University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 0 | 1 | 2011 |
| National Hospital Organisation Nagoya Medical Centre | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Pfizer | For profit | 1 | 0 | 1 | 2015 |
| Poole Hospital NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 1 | 1 | 2012 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2016 |
27 organizations
Page 1 / 2